Cohance Lifesciences Limited (BOM:543064)
India · Delayed Price · Currency is INR 405.75
-8.25 (-1.99%)
At close: Jun 19, 2026
Cohance Lifesciences Market Cap
Cohance Lifesciences has a market cap or net worth of 155.04 billion as of June 22, 2026. Its market cap has decreased by -60.37% in one year.
Market Cap
155.04B
Enterprise Value
157.01B
Revenue
22.69B
Ranking
n/a
PE Ratio
86.50
Stock Price
405.75
Market Cap Chart
Since March 9, 2020, Cohance Lifesciences's market cap has increased from 33.71M to 155.04B, an increase of 459,877.25%. That is a compound annual growth rate of 282.18%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jun 22, 2026 | 155.04B | -23.34% |
| Dec 31, 2025 | 202.22B | -30.24% |
| Dec 31, 2024 | 289.89B | 57.55% |
| Dec 29, 2023 | 184.00B | 46.05% |
| Dec 30, 2022 | 125.98B | 0.33% |
| Dec 31, 2021 | 125.56B | 9.05% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Mar 9, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| J. B. Chemicals & Pharmaceuticals | 351.51B |
| Rubicon Research | 224.36B |
| AstraZeneca Pharma India | 210.17B |
| Granules India | 194.73B |
| Caplin Point Laboratories | 190.50B |
| Jubilant Pharmova | 152.96B |
| CORONA Remedies | 114.28B |
| Viyash Scientific | 111.10B |